CAS: 3680-69-1; 4-Chloro-7H-Pyrrolo[2,3-D]Pyrimidine

相似化合物

479633-63-1 16019-34-4 1236033-21-8

上下游产品

7-deazahypoxanthine ethyl 2-cyano-4,4-diethoxybutyrate 6-amino-5-(2,2-diethoxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 2-thioxo-1,2,3,7-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one pyrimidine7-(benzoyloxyethoxymethyl)-4-chloropyrrolo2,3-dpyrimidine -2,3-O-(1-methylethylidene)-β-D-ribofuranosyl>-7H-pyrrolopyrimidine4-chloro-7-5-O-(1,1-dimethylethyl)dimethylsilyl-2,3-O-(1-methylethylidene)-β-D-ribofuranosyl-7H-pyrrolo2,3-dpyrimidine methyl>pyrrolopyrimidine4-chloro-7-1,3-bis(benzyloxy)-2-propoxymethylpyrrolo2,3-dpyrimidine pyrimidine>4'-chloro-4,7'bi7H-pyrrolo2,3-dpyrimidine

4-羟基吡咯并[2,3-D]嘧啶置于三氯氧磷体系中,用93%的收率获得产物4-氯吡咯并嘧啶
参考文献:β-高丙氨酰-Pna:具有β-片状骨架构象的β-肽的特例;高阶结构中的组织
标题:β-高丙氨酰-Pna:具有β-片状骨架构象的β-肽的特例;高阶结构中的组织
摘要:尽管 β-高丙氨酰肽核酸寡聚体具有 β-肽骨架,但它们的侧链含有核碱基,因此是 β-肽的一个有趣的特例.这些核碱基主要负责通过碱基配对和堆叠形成二级结构.我们已经使用腺嘌呤和 7-碳腺嘌呤研究了 β-高丙氨酰-Pna 低聚物的配对特性.简单的模型研究表明,Watson-Crick 和 Hoogsteen 配对平面的存在是嘌呤基 β-Pna 的固有结构特征.因此,腺嘌呤-β-Pna 六聚体和五聚体形成更高的有序结构,而缺少 Hoogsteen 配对位点的 7-碳腺嘌呤-β-Pna 六聚体则以双链形式配对.描述了腺苷酸和碳腺苷酸 β-核氨基酸的合成及其寡聚化.通过实验和简单的模型研究研究了配对模式和链方向.在 β-肽的背景下,β-Pna 寡聚体大部分倾向于以双链形式存在,并且更喜欢扩展的 β-片状骨架构象,除了观测到的 β-31 螺旋外,它提供了一个有趣的结构基序.肽.
DOI:10.1002/(Sici)1099-0690(199805)1998:5<827::Aid-Ejoc827>3.0.Co;2-B

专利信息

专利号:US-8309716-B2
优先权日:2005-07-29
标题 :Pyrrolo[2,3-d]pyrimidine derivatives: their intermediates and synthesis
发明人：RUGGERI SALLY GUT; HAWKINS JOEL M; MAKOWSKI TERESA M; RUTHERFORD JENNIFER L; URBAN FRANK J
权利人:RUGGERI SALLY GUT; HAWKINS JOEL M; MAKOWSKI TERESA M; RUTHERFORD JENNIFER L; URBAN FRANK J; PFIZER
摘要:This invention relates to methods and intermediates useful for the synthesis of pyrrolo[2,3-d]pyrimidine compounds. Specifically novel synthetic methods and intermediates for the synthesis of 3-{(3R,4R)-4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino}-piperidin-1-yl)-3-oxo-propionitrile and its corresponding citrate salt are disclosed.

专利号:WO-2008148560-A1
优先权日:2007-06-07
标题 :New hybrid compounds of nucleobases and organic redox molecules and their use
发明人：ASAFTEI SIMONA CARMEN
权利人:UNIV OSNABRUECK; ASAFTEI SIMONA CARMEN
摘要:The present invention relates to new compounds as well as methods for the synthesis of the same, said compounds comprise a redox active group, e.g. a 4,4-bipyridine (viologen), a 1,2-di(4-pyridyl)ethane, a 2,7-diazapyrene or 2,9-diazaperylene group and a N-heterocyclic nucleobase (HB), also referred to as base.

专利号:US-12441733-B2
优先权日:2018-03-26
标题:Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors
发明人：ARISTA LUCA; HEBACH CHRISTINA; HOLLINGWORTH GREGORY JOHN; HOLZER PHILIPP; IMBACH-WEESE PATRICIA; LORBER JULIEN; MACHAUER RAINER; SCHMIEDEBERG NIKO; VULPETTI ANNA; ZOLLER THOMAS
权利人:NOVARTIS AG
摘要:The invention relates to compounds of the formulae (I), (III), (IIIa), (XXIa), (XXIII), and/or (XLVI)or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to use of the compounds in the treatment of disease.

专利号:US-9828380-B2
优先权日:2015-04-10
标题 :Efficient method for the preparation of tofacitinib citrate
发明人：BONANOMI JACOPO; DEFIORE STELLA; NOVO BARBARA
权利人:OLON SPA
摘要:Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises:n 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6. Salification of intermediate II to give tofacitinib monocitrate (I)

专利号:US-6271370-B1
优先权日:1999-05-11
标 题 :Process for the synthesis of nucleoside analogs
发明人：SCOTT ROBERT W
权利人:PFIZER
摘要:The present invention relates to an improved method for synthesizing nucleosides with a low α:β anomeric ratio. The method comprises coupling a protected furanosyl halide and an appropriately protected heterocycle in the presence of a nucleophilic polar solvent and a strong base.

专利号:US-10562904-B2
优先权日:2015-12-31
标 题:Synthesis process of ruxolitinib
发明人：ZHANG XIQUAN; ZHANG AIMING; ZHOU ZHOU; YANG LEILEI; YAO HUADONG; ZHU XUEYAN; WANG HUBO
权利人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
摘要:The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.